Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BeyondSpring Inc. (BYSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5900+0.0700 (+4.61%)
At close: 04:00PM EDT
1.6600 +0.07 (+4.40%)
After hours: 07:56PM EDT
Advertisement

BeyondSpring Inc.

28 Liberty Street
39th Floor
New York, NY 10005
United States
646 305 6387
https://www.beyondspringpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Dr. Lan HuangCo-Founder, Chairman & CEON/AN/A1971
Dr. G. Kenneth LloydChief Scientific OfficerN/AN/A1944
Dr. Ramon W. MohanlalExec. VP of R&D, Chief Medical Officer and DirectorN/AN/A1958
Mr. Linqing JiaCo-FounderN/AN/AN/A
Stephen KilmerHead of Investor RelationsN/AN/AN/A
Mr. Gregg RussoSr. VP of HRN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Corporate Governance

BeyondSpring Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement